After 30 Years Of Dreams, A Wake-Up Call For NASA

In March, a panel of experts, convened by the National Research Council to advise the administration on the latest redesign of the space station Freedom, concluded that the proposed $30 billion monster was unsuited for scientific research. Surprisingly, space station proponents made little attempt to refute this harsh judgment. In a letter to NASA administrator Richard Truly, Vice President Dan Quayle, head of the National Space Council, simply dismissed the concerns of the scientific communit

Written byRobert Park
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

In a letter to NASA administrator Richard Truly, Vice President Dan Quayle, head of the National Space Council, simply dismissed the concerns of the scientific community; science, he shrugged, is only one motivation for building a space station--and not even the most important one. In an apparent reference to the panel's concern that there would be insufficient electrical power on board for scientific experiments, Quayle wrote: "The importance of the Space Station is not in the power of its circuits; it is in the size of the dream."

There you have it. It's the dream that matters. And so it was at the birth of the space station initiative, Jan. 25, 1984, on the occasion of President Ronald Reagan's State of the Union address. "We can follow our dreams to distant stars," he said, "living and working in space for peaceful economic and scientific gain. Tonight I am directing NASA ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies